Lead Optimization. ▇▇▇▇▇▇▇ shall, concurrent with sending the Company Selection Notice, make the payment(s) to Cengent as indicated in Paragraph above. Also, Company shall pay $150,000 to Cengent upon selecting by Company of a Lead Optimization Compound or a derivative (e.g., homologs, analogs, polymorphs, isomers, prodrugs and formulations of the Lead Optimization Compound), payable as a number of shares of Company stock based on the most recent stock price accepted by an independent investor in an arm's length transaction.
Appears in 2 contracts
Sources: Genes to Leads Agreement (AngioGenex, Inc.), Genes to Leads Agreement (AngioGenex, Inc.)